Business Context and Reporting Period
The filing is Selecta Biosciences, Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2020; the source text does not identify Cartesian Therapeutics. Selecta was a clinical-stage biotechnology company developing its ImmTOR immune-tolerance platform for biologic therapies, gene therapy, and autoimmune diseases. It had no approved products or product sales.
Key Financial Metrics
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Grant and collaboration revenue | $0 | $0.013 million | $0 | $0.023 million |
| Research and development expense | $10.730 million | $12.134 million | $25.454 million | $19.487 million |
| General and administrative expense | $5.637 million | $4.114 million | $9.735 million | $8.627 million |
| Net loss | $24.081 million | $16.394 million | $43.701 million | $28.468 million |
| Net loss per share | $0.25 | $0.37 | $0.46 | $0.68 |
| Net cash used in operating activities | Not separately provided | Not separately provided | $23.506 million | $27.437 million |
- Cash and cash equivalents were $59.730 million at June 30, 2020, compared with $89.893 million at December 31, 2019. Total cash, cash equivalents, and restricted cash were $61.387 million.
- Accumulated deficit was $379.454 million, compared with $335.753 million at year-end 2019.
- Total liabilities were $88.258 million and stockholders’ deficit was $13.052 million at June 30, 2020.
- Debt consisted primarily of the SVB term loan, with $14.0 million of principal outstanding and $8.384 million classified as current.
- Operating lease liabilities totaled $11.768 million, reflecting the new eight-year headquarters lease.
- Warrant liabilities were $32.767 million and generated an $8.385 million non-cash fair-value charge during the first six months.
Material Changes Versus the Prior Comparable Period
- Second-quarter net loss increased $7.687 million, primarily because of the $7.539 million warrant-liability fair-value charge and higher general and administrative expense, partly offset by lower R&D expense.
- Six-month net loss increased $15.233 million. R&D expense rose 31% as the company prepared for SEL-212 Phase 3 trials, continued the COMPARE trial, and expanded its AskBio gene-therapy program.
- Six-month operating cash burn improved to $23.506 million from $27.437 million, while total cash, cash equivalents, and restricted cash declined $30.164 million.
- The company sold 1.069 million shares through its at-the-market program for $2.137 million of net proceeds during the first six months.
- Warrant exercises reduced warrant liabilities by approximately $17.167 million, but revaluation increased the remaining liability by $8.385 million.
- The company entered into the $2.0 million Sarepta research license and option agreement, but recognized no related revenue during the quarter because no deliveries occurred.
Guidance, Outlook, Risks, and Unusual Items
- Management expected its June 30 cash and restricted cash, together with the expected $75 million Sobi license payment and $25 million Sobi equity investment, to fund operations and capital expenditures into the first quarter of 2023. The Sobi transactions closed after quarter-end on July 28 and July 31, 2020, respectively.
- Under the Sobi agreement, Sobi licensed SEL-212 outside Greater China, agreed to fund the planned Phase 3 program, and provided potential milestone payments of up to $630 million plus tiered royalties. These potential payments were contingent and were not recognized as revenue at June 30.
- Management expected to report top-line COMPARE data in the third quarter of 2020 and planned to commence two SEL-212 Phase 3 trials in the third quarter, subject to COVID-19 impacts.
- The company planned to file an IND for the AskBio MMA gene-therapy program in the first quarter of 2021 and an IND for its lead autoimmune program in 2021.
- COVID-19 could delay enrollment, site operations, clinical timelines, regulatory interactions, manufacturing, supply, and funding access. Management stated that supply was adequate to initiate the planned SEL-212 Phase 3 program and AskBio gene-therapy trial as of the filing date.
- The company remained dependent on additional financing and expected continuing operating losses. Additional equity financing could dilute shareholders, while debt or collaborations could impose restrictive terms or require relinquishing rights.
- A putative shareholder derivative action was filed on August 3, 2020 alleging fiduciary-duty breaches and corporate waste relating to the December 2019 private placement. The company expected to file a motion to dismiss; the filing does not provide a quantified potential loss.
- The company had no material litigation pending as of June 30, but disclosed ordinary-course contractual disputes and contingencies, including potential milestone payments under the 3SBio license and diligence obligations under the MIT license.
Important Facts for Investors to Verify
- Confirm that the filing belongs to Selecta Biosciences, Inc., not Cartesian Therapeutics.
- Verify receipt and accounting treatment of the $75 million Sobi upfront payment and the $25 million Sobi private-placement proceeds after quarter-end.
- Monitor COMPARE results, the initiation and funding of the SEL-212 Phase 3 program, and any COVID-19-related delays.
- Assess liquidity after incorporating operating cash burn, debt maturities, lease obligations, contingent warrant repurchase provisions, and additional financing needs.
- Review the valuation sensitivity of the $32.767 million Level 3 warrant liability and its potential effect on future earnings.
- Track the shareholder derivative litigation and any effect on legal costs, governance, or the December 2019 financing.